Myopia control means

US9594257B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• Brien Holden Vision Institute Limited · AU

Inventors

• Aldo Abraham Martinez · Fort Worth, US
• Arthur Ho · Sydney, AU
• Padmaja Rajagopal Sankaridurg · Sydney, AU
• Percy Fabian Lazon · Sydney, AU
• Brien Anthony Holden · Sydney, AU
• Rick Payor · Cumming, US
• Gregor Schmid · Ainring, DE

Key dates

• Filing date: Jan 21, 2014
• Grant date: Mar 14, 2017
• Expiry date: Jan 21, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G02C2202/24
• WIPO field: Optics
• WIPO sector: Instruments

Abstract

Sets, kits or stocks of anti-myopia contact or spectacle lenses, along with methods for their use, that do not require a clinician to measure peripheral refractive error in the eyes of myopic patients. Extensive surveys have shown that lenses having peripheral powers or defocus set in accordance with central corrective power will cover almost all normal myopes not worse than −6D central refractive error. In one example, a kit or set of lenses (50, FIG. 15) can have multiple parts or sub-sets (52, 54) each comprising a compartmented container (56a, 56b) with lenses (58a, 58b) arranged according to increments of central corrective power (59a, 59b). The lenses (58a) of the first part (52) have four steps (60a, 61a, 62a, 64a) of peripheral power or defocus to provide therapeutic effect and, while the lenses (58b) of the second part (54) also have four steps (60b, 61b, 62b, 64b), the level of therapeutic effect is higher. Other examples of sets, kits and stocks, as well as examples of lenses themselves, are disclosed together with methods of use.